Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Express Scripts
Mallinckrodt
Merck
Johnson and Johnson

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Patent: 9,388,239

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,388,239
Title:Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
Abstract: Murine and humanized anti-human VEGF antibodies and uses are disclosed. The anti-human VEGF antibodies of the invention have higher binding affinity for human VEGF-A, are stronger inhibitors of the VEGF-A induced proliferation of endothelial cells in culture as compared with anti-human VEGF antibodies in the art. Moreover, these antibodies cross react with human VEGF-B. The antibodies of the invention inhibit tumor growth in vivo in greater extent than Bevacizumab when administered at the same dosage.
Inventor(s): Baldi; Alberto (Ciudad Autonoma de Buenos Aires, AR), Gongora; Adrian Daniel (Ciudad Autonoma de Buenos Aires, AR), Mladovan; Alejandro Gustavo (Ciudad Autonoma de Buenos Aires, AR)
Assignee: Consejo Nacional De Investigation Cientifica (Cuidad Autonoma de Buenos Aires, AR) LABORATORIO Pablo Cassana SRL (Ciudad Autoonoma de Buenos Aries, AR)
Application Number:14/267,504
Patent Claims:see list of patent claims

Details for Patent 9,388,239

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Consejo Nacional De Investigation Cientifica (Cuidad Autonoma de Buenos Aires, AR) LABORATORIO Pablo Cassana SRL (Ciudad Autoonoma de Buenos Aries, AR) 2039-02-26 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Consejo Nacional De Investigation Cientifica (Cuidad Autonoma de Buenos Aires, AR) LABORATORIO Pablo Cassana SRL (Ciudad Autoonoma de Buenos Aries, AR) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Merck
Colorcon
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.